After Reviewing Brief Product Profiles, Surveyed Physicians Believe that Likely Candidates for Late-Phase Chronic Kidney Disease Products from AbbVie, Mitsubishi Tanabe, Eli Lilly, Concert, Fibrogen and Pfizer are Typically Stage 3b and 4 Patients
PCPs are Most Likely to Make the Initial CKD Diagnosis, Making Them an Important Target for Manufacturers, According to a New Report from BioTrends Research Group
EXTON, Pa., July 11, 2013 /PRNewswire/ — BioTrends Research Group, one of the world’s leading research and advisory firms for specialized biopharmaceutical issues, finds that, for late-phase products for chronic kidney disease (CKD) patients–including AbbVie’s altrasentan, Concert Pharmaceuticals’ CTP-499, Mitsubishi Tanabe’s MP-146/AST-120, Fibrogen’s FG3019, Pfizer’s PF00487791 and PF04634817 and Eli Lilly’s LY2382770–the percentage of likely candidates is typically, but not always highest, in Stage 3b and Stage 4. TreatmentTrends: Chronic Kidney Disease Stages 1-5 ND (US) also finds that, among physicians who treat CKD, familiarity with new products in development is low, but interest is generally high after reviewing brief product profiles.
The report also finds that among 250 surveyed nephrologists, endocrinologists and primary care physicians (PCPs), PCPs are significantly more likely than other physician groups to make the initial diagnosis of CKD, and PCPs account for the majority (51 percent) of the CKD non-dialysis patient referrals that nephrologists receive. Physicians report that CKD patients are most often diagnosed in Stage 3; nephrologists report CKD patients are diagnosed significantly later in the disease process compared with what PCPs and endocrinologists report.
“Eighty-six percent of physicians believe that the ideal timing for a new CKD agent designed to slow disease progression would be either during treatment of patients with early symptoms or for asymptomatic patients,” said BioTrends Research Group Director Rob Dubman. “Given this, these patients are likely to be with the PCP or endocrinologist at that point during the disease progression making these physician types important. Manufacturers in this market should therefore consider, at least to some extent, the impact of the PCP and endocrinologist in regard to patient referral and treatment.”
Patient compliance is also a key issue in this patient population. The report finds that patients tend to be most compliant with antihypertensive agents and erythropoiesis stimulating agents (ESAs) and least compliant with phosphate binders and lifestyle changes.
TreatmentTrends: Chronic Kidney Disease Stages 1-5 ND (US) is a report series designed to track physician perception of the CKD non-dialysis patient population, including referral patterns, patient load, percentage of patients on current treatments, screening protocols, diagnosis patterns, frequency of comorbidities, unmet needs and reaction (familiarity, interest and percentage of patients as likely candidates) to new products in development. A total of 250 physicians are included in the third wave sample frame, including 100 nephrologists, 50 endocrinologists and 100 primary care physicians. The third wave of this report published in June 2013.
About BioTrends Research Group
BioTrends Research Group provides syndicated and custom primary market research to pharmaceutical manufacturers competing in clinically evolving, specialty pharmaceutical markets. For information on BioTrends publications and research capabilities, please visit www.bio-trends.com. BioTrends is a Decision Resources Group company.
About Decision Resources Group
Decision Resources Group is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources Group at www.DecisionResourcesGroup.com.
All company, brand, or product names contained in this document may be trademarks of their respective holders.
For more information, contact:
Decision Resources Group
SOURCE BioTrends Research Group